WX

WebserviceX

Agentic AI Equity Research

Coverage blotter·Stock analysis hub·Note 2026-07-01·Latest →

Bristol Myers Squibb (BMY) Stock Analysis

OW

BMY Equity Research — OVERWEIGHT — July 2026

← AMGNCVS →

Rating date

Jul 1, 2026

40 days ago

Desk view

OW

5D move

—

Awaiting market data

Peer rank

63p

Research history

2026-08-072026-07-202026-07-012026-06-252026-06-182026-06-162026-06-082026-06-02+1 more

Investment card · BMY

Here is my analysis of BMY (Bristol-Myers Squibb) as of the July 1, 2026 close.

Desk rating

OW

Tactical OW · 12M OW

Horizon

Short to medium term

Confidence

Low

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Bias

OVERWEIGHT

Catalysts

  • BMY's year-long uptrend remains structurally intact, with price holding well above the rising 200-day SMA.
  • Short-term momentum has gone flat — the declining 50-day SMA and neutral RSI suggest the stock is in a consolidation/pause phase after the strong run.
  • The MACD is coiling near zero, which often precedes a directional decision; a move into positive territory would be a near-term bullish trigger.

Risks

  • Event-driven repricing risk if expectations diverge from incoming evidence.

Market chart

Price context alongside the research narrative.

BMY Research Note

Full desk note for Jul 1, 2026. Use tabs for catalysts, valuation and risks, or open the full note.

29 min read

WebserviceX · Agentic Research Desk

BMY Equity Research Note

Published Jul 1, 2026 · Desk view OVERWEIGHT · Generated 2026-07-02T20:25:14Z · Maintained by Walter Vijayakumar · Methodology · Track record

BMY Stock Rating Summary

BMY bias

OVERWEIGHT

Horizon

Short to medium term

BMY key risk

Event-driven repricing risk if expectations diverge from incoming evidence.

BMY catalyst watch

BMY's year-long uptrend remains structurally intact, with price holding well above the rising 200-day SMA.

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Confidence

Low

How the call aged · 5D

—Awaiting market dataPeer 63p
Expand

Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-07-02T20:45:14.020739+00:00.

5D move

—

2026-07-01 → awaiting

Outcome

Awaiting market data

5D trend

+2.62%

Vol (20D ann.)

+30.09%

vs SPY: +0.91%

Close 56.44 → — (USD, vendor closes)

Batch scorecard · 2026-07-01 · BMY

Publish QC

passed
Expand

Pipeline fingerprint 2f45a102687f75c0

Trace b9b1a75c…

No QC issues recorded.